Page last updated: 2024-11-04

vorinostat and Embolism, Pulmonary

vorinostat has been researched along with Embolism, Pulmonary in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Heymann, WR1

Reviews

1 review available for vorinostat and Embolism, Pulmonary

ArticleYear
Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
    Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:4

    Topics: Antineoplastic Agents; Fatigue; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; H

2008